Skip to main content
. Author manuscript; available in PMC: 2016 Dec 15.
Published in final edited form as: Cell Rep. 2015 Nov 25;13(10):2159–2173. doi: 10.1016/j.celrep.2015.10.073

Figure 6. PU-H71 Ablates In Vivo LSCs of Primary AML Samples with High pSTAT5 Levels.

Figure 6

(A) Immunoblots (left) and graphed summary (right; means ± SEM) for the indicated proteins in M0-91 or HEL cells-engrafted mice after one dose of PU-H71 (75 mg/kg).

(B) Schematic representation for the in vivo treatment of MOLM-13-GFP-Luc xenografts.

(C) Whole-body luciferase imaging of MOLM-13-GFP-Luc xenografts before and during treatment with PU-H71.

(D) Top panel: representative plots for mouse (mCD45) and human (hCD45) BM cells harvested from MOLM-13-GFP-Luc xenografts after 2 weeks of treatment with PU-H71. Bottom panel: percent human cells in xenografts treated with either PBS or PU-H71 (PU) is shown.

(E) Schematic representation for the in vivo AML-patient-derived xenograft (PDX) treatments.

(F) Correlations between p-STAT5 (y axis; left panel) and pS6 (y axis; right panel) and decreased tumor burden after PU-H71 treatment (x axis).

(G) Percent decrease in tumor burden after treatment with PU-H71 for seven PDX-AML xenograft cohorts grouped by their relative levels of pSTAT5 and pS6.

(H) Percent leukemia engraftment in secondary transplants for the indicated PDX-AML xenograft cohorts grouped by their relative levels of pSTAT5 and pS6.

(I) CFUs of murine bone marrow cells evaluated from disease-free C57BL6 mice treated for 3 weeks with either PBS or PU-H71.